Extended Data Fig. 6: PFS according to tumor TMB. | Nature Medicine

Extended Data Fig. 6: PFS according to tumor TMB.

From: An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Extended Data Fig. 6

TMB < 10 mutations/Mb was associated with shorter PFS when combining the arms irrespective of treatment (HR 1.904 [1.178; 3.078]) Logrank test, P = 0.007. Analysis performed: Kaplan Meier analysis according to the TMB at baseline and Cox model for HR. HR, hazard ratio; PFS, progression-free survival; TMB, tumor mutational burden.

Back to article page